Katy H. Goldsborough
Advanced in Richter Syndrome

Dr. Katy H. Goldsborough

Hematology | Oncology
3745 Highland Ave 2nd Fl, 
Downers Grove, IL 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Richter Syndrome
3745 Highland Ave 2nd Fl, 
Downers Grove, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Katy Goldsborough is a Hematologist and an Oncologist in Downers Grove, Illinois. Dr. Goldsborough is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Breast Cancer, Leukocytosis, Paget Disease of the Breast, and Pleuropulmonary Blastoma.

Her clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
McGaw Medical Center of Northwestern University, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine, Hematology
Fellowships
Northwestern University Medical Center, Hematology/Oncology
Hospital Affiliations
Advocate Illinois Masonic Medical Center
Advocate Good Samaritan Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Advocate Good Samaritan Cancer Center
3745 Highland Ave 2nd Fl, Downers Grove, IL 60515

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Distinguished in Richter Syndrome
Dr. Shuo Ma
Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Shuo Ma
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (21.0 miles away)
866-587-4322
Experience:
31+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shuo Ma is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Ma has been practicing medicine for over 31 years and is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Distinguished in Richter Syndrome
Dr. Nadia N. Khan
Hematology | Oncology | Transplant Surgery
Distinguished in Richter Syndrome
Dr. Nadia N. Khan
Hematology | Oncology | Transplant Surgery

Rush University Medical Group

1520 W Harrison St, 
Chicago, IL 
 (18.8 miles away)
312-942-5904
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nadia Khan is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, and Chronic Lymphocytic Leukemia (CLL). Dr. Khan is currently accepting new patients.

Distinguished in Richter Syndrome
Dr. Parameswaren Venugopal
Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Parameswaren Venugopal
Hematology | Oncology

Rush University Medical Group

1620 W Harrison St, 
Chicago, IL 
 (18.0 miles away)
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Parameswaren Venugopal is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Venugopal is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Venugopal is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldsborough's expertise for a condition
ConditionClose
    View All 75 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile